Trial Profile
A phase II study of Nivolumab for relapsed/refractory adult T-cell leukemia/lymphoma (ATL)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adult T-cell leukaemia-lymphoma
- Focus Therapeutic Use
- 12 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 23 Jul 2022 Planned End Date changed from 31 Mar 2023 to 30 Sep 2027.
- 01 Jun 2022 Planned number of patients changed from 30 to 22.